Trial Profile
Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 May 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 26 Apr 2023 Planned End Date changed from 1 Jan 2023 to 1 Jun 2025.
- 26 Apr 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2025.
- 17 Jun 2022 Results of an analysis assessed the measurable residual disease by next generation sequencing presented at the 27th Congress of the European Haematology Association